PharmaResearchBio Registers Patent for 'Increased In Vivo Persistence of Botulinum Toxin'

PN Addition Prolongs Muscle Relaxation Effect by Up to 2.3 Times... Increased Applicability Anticipated

PharmaResearchBio (CEO SeungGul Baek, Alex Won), a subsidiary of PharmaResearch's toxin division, announced earlier this month that it had registered a patent for technology that enhances the in vivo persistence of botulinum toxin formulations.

The official patent title is “Long-acting formulation with increased in vivo persistence of botulinum toxin, including DNA fragment mixture and botulinum toxin.”

This technology involves adding polynucleotides (PN) to botulinum toxin type A, which can extend muscle relaxation by up to 2.3 times.

A representative from PharmaResearchBio stated, “This patented technology significantly extends the efficacy duration of botulinum toxin formulations, potentially reducing the maximum number of injections required for therapeutic and cosmetic applications,” and added, “We expect it to be widely applied across various medical fields where the persistence of botulinum toxin is crucial.”

Meanwhile, PharmaResearchBio produces and exports botulinum toxin Re N Tox injections in 100-unit and 200-unit packages overseas. In February, it obtained domestic product approval for Re N Tox 100-unit.